RU2658004C2 - Получение полилактидно-полигликолидных микрочастиц, характеризующихся сигмоидальным профилем высвобождения - Google Patents

Получение полилактидно-полигликолидных микрочастиц, характеризующихся сигмоидальным профилем высвобождения Download PDF

Info

Publication number
RU2658004C2
RU2658004C2 RU2016101418A RU2016101418A RU2658004C2 RU 2658004 C2 RU2658004 C2 RU 2658004C2 RU 2016101418 A RU2016101418 A RU 2016101418A RU 2016101418 A RU2016101418 A RU 2016101418A RU 2658004 C2 RU2658004 C2 RU 2658004C2
Authority
RU
Russia
Prior art keywords
phase
microparticles
release
risperidone
organic solvent
Prior art date
Application number
RU2016101418A
Other languages
English (en)
Russian (ru)
Other versions
RU2016101418A (ru
Inventor
Евангелос Каравас
Эфтимиос Кутрис
Сотириа ХЕТИДУ
Теофанис Мантурлиас
Йоргия Папаниколау
Original Assignee
Фарматен С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фарматен С.А. filed Critical Фарматен С.А.
Publication of RU2016101418A publication Critical patent/RU2016101418A/ru
Application granted granted Critical
Publication of RU2658004C2 publication Critical patent/RU2658004C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/12—Powdering or granulating
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/12—Powdering or granulating
    • C08J3/14—Powdering or granulating by precipitation from solutions
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2300/00—Characterised by the use of unspecified polymers
    • C08J2300/16—Biodegradable polymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2367/00—Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
    • C08J2367/04—Polyesters derived from hydroxy carboxylic acids, e.g. lactones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2016101418A 2013-06-20 2014-06-18 Получение полилактидно-полигликолидных микрочастиц, характеризующихся сигмоидальным профилем высвобождения RU2658004C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2013001821 2013-06-20
EPPCT/EP2013/001821 2013-06-20
PCT/EP2014/001652 WO2014202214A1 (en) 2013-06-20 2014-06-18 Preparation of polylactide-polyglycolide microparticles having a sigmoidal release profile

Publications (2)

Publication Number Publication Date
RU2016101418A RU2016101418A (ru) 2017-07-25
RU2658004C2 true RU2658004C2 (ru) 2018-06-19

Family

ID=51022802

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016101418A RU2658004C2 (ru) 2013-06-20 2014-06-18 Получение полилактидно-полигликолидных микрочастиц, характеризующихся сигмоидальным профилем высвобождения

Country Status (15)

Country Link
US (1) US9943484B2 (enExample)
JP (1) JP6464154B2 (enExample)
CN (1) CN105308101B (enExample)
AU (1) AU2014283692B2 (enExample)
CA (1) CA2916301C (enExample)
DK (1) DK3010962T4 (enExample)
ES (1) ES2640486T5 (enExample)
FI (1) FI3010962T4 (enExample)
HU (1) HUE036141T2 (enExample)
LT (1) LT3010962T (enExample)
PT (1) PT3010962T (enExample)
RU (1) RU2658004C2 (enExample)
SA (1) SA515370296B1 (enExample)
WO (1) WO2014202214A1 (enExample)
ZA (1) ZA201509354B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170036768A (ko) * 2014-07-30 2017-04-03 메르크 파텐트 게엠베하 미세결정성 셀룰로오스를 포함하는 직접 압축성 조성물
JP2016102093A (ja) * 2014-11-28 2016-06-02 ニプロ株式会社 塩基性の求核化合物を含有するマイクロカプセルの製造方法
US20170079985A1 (en) 2015-09-21 2017-03-23 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
JP2020511483A (ja) 2017-03-20 2020-04-16 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 徐放性オランザピン製剤
KR102047983B1 (ko) * 2017-11-30 2019-11-22 주식회사 지투지바이오 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법
GR1009870B (el) * 2019-07-09 2020-11-12 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει ενα ατυπο αντιψυχωσικο φαρμακο και μεθοδος παρασκευης αυτου
WO2021134623A1 (zh) * 2019-12-31 2021-07-08 广州帝奇医药技术有限公司 一种叔胺药物组合物及其产业化批量制备方法
EP4125823A1 (en) 2020-03-30 2023-02-08 Biological E Limited Risperidone microspheres, process for their prepartion and uses thereof
KR102259589B1 (ko) * 2020-11-30 2021-06-02 (주)인벤티지랩 미소구체 제조 시스템 및 미소구체 제조 방법
EP4277661A1 (en) 2021-01-18 2023-11-22 Anton Frenkel Pharmaceutical dosage form
EP4297753A4 (en) * 2021-02-24 2025-01-01 Oakwood Laboratories, Llc Microsphere formulations comprising lurasidone and methods for making and using the same
WO2023281406A1 (en) 2021-07-06 2023-01-12 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
GR1010327B (el) * 2021-10-06 2022-10-17 Φαρματεν Α.Β.Ε.Ε., Παρατεταμενης αποδεσμευσης ενεσιμο φαρμακευτικο σκευασμα λεβοθυροξινης και μεθοδος παρασκευης αυτου
WO2025135778A1 (ko) * 2023-12-18 2025-06-26 주식회사 포스테라헬스사이언스 약물의 특성에 따른 활성형 미립자의 제조 방법, 이의 제조 방법으로 제조된 활성형 미립자 및 상기 활성형 미립자를 이용한 약물을 포함하는 장기 지속 제형의 제조 방법
WO2025207396A1 (en) * 2024-03-27 2025-10-02 Avidence Therapeutics, Inc. Microsphere-based injectable rofecoxib formulation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288496A (en) * 1990-05-15 1994-02-22 Stolle Research & Development Corporation Growth promoters for animals
WO2000040221A1 (en) * 1998-12-30 2000-07-13 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
RU2201214C2 (ru) * 1996-05-07 2003-03-27 Алкермес Контроулд Терапьютикс Инк. Ii Микрочастицы и способ их получения

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478564A (en) * 1990-02-22 1995-12-26 Teva Pharmaceutical Industries, Ltd. Preparation of microparticles for controlled release of water-soluble substances
AU722884B2 (en) * 1996-01-24 2000-08-10 United States Government Represented By The Secretary Of The Army Novel "burst-free" sustained release poly-(lactide/glycolide) microspheres
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US7690026B2 (en) * 2005-08-22 2010-03-30 Microsoft Corporation Distributed single sign-on service

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288496A (en) * 1990-05-15 1994-02-22 Stolle Research & Development Corporation Growth promoters for animals
RU2201214C2 (ru) * 1996-05-07 2003-03-27 Алкермес Контроулд Терапьютикс Инк. Ii Микрочастицы и способ их получения
WO2000040221A1 (en) * 1998-12-30 2000-07-13 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile

Also Published As

Publication number Publication date
DK3010962T4 (da) 2023-04-17
DK3010962T3 (en) 2017-10-23
ES2640486T5 (es) 2023-04-28
AU2014283692A1 (en) 2016-01-21
AU2014283692B2 (en) 2017-04-27
ZA201509354B (en) 2017-07-26
CA2916301C (en) 2020-01-07
CN105308101B (zh) 2018-10-23
WO2014202214A1 (en) 2014-12-24
US20160143851A1 (en) 2016-05-26
LT3010962T (lt) 2017-09-25
RU2016101418A (ru) 2017-07-25
PT3010962T (pt) 2017-09-05
US9943484B2 (en) 2018-04-17
SA515370296B1 (ar) 2017-10-12
ES2640486T3 (es) 2017-11-03
JP6464154B2 (ja) 2019-02-06
JP2017507895A (ja) 2017-03-23
CN105308101A (zh) 2016-02-03
CA2916301A1 (en) 2014-12-24
FI3010962T4 (fi) 2023-05-04
HUE036141T2 (hu) 2018-06-28

Similar Documents

Publication Publication Date Title
RU2658004C2 (ru) Получение полилактидно-полигликолидных микрочастиц, характеризующихся сигмоидальным профилем высвобождения
EP1925297B2 (en) Method for preparing microparticles having a selected polymer molecular weight
Lee et al. Poly (lactic‐co‐glycolic acid) devices: Production and applications for sustained protein delivery
AU2004277419B2 (en) Nanoparticulate therapeutic biologically active agents
Dinarvand et al. Effect of surfactant HLB and different formulation variables on the properties of poly-D, L-lactide microspheres of naltrexone prepared by double emulsion technique
Blanco-Prı́eto et al. In vitro and in vivo evaluation of a somatostatin analogue released from PLGA microspheres
US12036323B2 (en) Biodegradable polymer microsphere compositions for parenteral administration
RS61209B1 (sr) Dobijanje plga mikrosfera napunjenih peptidima sa karakteristikama kontrolisanog oslobađanja
Graves et al. Effect of different ratios of high and low molecular weight PLGA blend on the characteristics of pentamidine microcapsules
Xiao et al. The effect of polymer blends on initial release regulation and in vitro-in vivo relationship of peptides loaded PLGA-Hydrogel Microspheres
KR20220127254A (ko) 카리프라진 방출 제형
Iwata et al. Selection of the solvent system for the preparation of poly (D, L-lactic-co-glycolic acid) microspheres containing tumor necrosis factor-alpha (TNF-α)
EP1924242B1 (en) Pharmaceutical composition comprising anastrozole
EP3010962B2 (en) Preparation of polylactide-polyglycolide microparticles having a sigmoidal release profile
Schutzman Mechanistic Evaluation of Early Phases of Drug Release From Polymer Microparticles Prepared by Atomization Techniques
Pasam et al. Evaluation and comparison of the formulations of Amlodipine-loaded bovine serum albumin and egg albumin microspheres
Islami et al. Preparation and Characterization of Estradiol Valerate Microspheres Using Biodegradable Polymers: Preparation of estradiol valerate microspheres